| CEO Name | Emma Walmsley |
| Nationality | United Kingdom |
| Net Worth Estimation | $40 million |
Emma Walmsley's estimated net worth of around $40 million is largely due to her compensation as CEO of GlaxoSmithKline, including annual salary, bonuses, and stock awards tied to company performance. Additional equity holdings and long-term incentives from her tenure at both GSK and previously at L'Oreal further augment her net wealth.
Emma Walmsley, CEO of GlaxoSmithKline in the personal care business category, has an estimated net worth of $40,000,000. Her net worth is 44.94% of the maximum value ($90,000,000) and 40 times the minimum value ($1,000,000) within this category.
Business Category: Personal care
Minimum Net Worth (estimation): 1000000 USD
Maximum Net Worth (estimation): 90000000 USD
Emma Walmsley Performance in GlaxoSmithKline
Emma Walmsley, CEO of GlaxoSmithKline, demonstrates visionary leadership focused on innovation and patient-centric strategies. Her decision-making emphasizes digital transformation, research investment, and portfolio optimization, driving significant growth and efficiency. Under Walmsley's leadership, GSK has strengthened its pharmaceutical pipeline and boosted shareholder value, positioning the company as a competitive global healthcare leader.
Latest News
GSK's CEO Emma Walmsley to Depart, Luke Miels to Succeed Her in 2026
Emma Walmsley, the first female CEO of big pharma, will step down on Dec 31, 2025, after leading major transformations in GSK's portfolio and R&D, with Luke Miels appointed as her successor effective Jan 1, 2026. Under Walmsley, GSK shifted focus toward specialty medicines and vaccines, boosting revenue and pipeline prospects, while Miels, previously chief commercial officer, prepares to lead at a pivotal time for the company.
Source: http://www.biopharmadive.com/news/emma-walmsley-retire-gsk-ceo-luke-miels/761344/